Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.

Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C.

J Bone Miner Res. 1996 Jun;11(6):835-42.

PMID:
8725181
2.

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.

Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL.

J Bone Miner Res. 1998 Nov;13(11):1747-54.

3.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.

Arch Intern Med. 2004 Apr 26;164(8):871-9.

PMID:
15111373
4.

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.

Osteoporos Int. 1999;10(4):330-6. Erratum in: Osteoporos Int 1999;10(5):433.

PMID:
10692984
5.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
6.
7.

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C.

N Engl J Med. 1997 Dec 4;337(23):1641-7.

8.

Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.

Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.

Osteoporos Int. 2003 Oct;14(10):793-800. Epub 2003 Aug 29.

PMID:
12955333
9.

[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):269-73. Chinese.

PMID:
15059505
10.

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.

Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB.

Osteoporos Int. 2003 Oct;14(10):814-22. Epub 2003 Aug 28.

PMID:
14610642
11.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
12.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.

Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.

Chin Med J (Engl). 2003 Aug;116(8):1127-33.

PMID:
12935394
13.

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD.

Arch Intern Med. 2000 Dec 11-25;160(22):3444-50.

PMID:
11112238
14.

Clinical efficacy of raloxifene in postmenopausal women.

Agnusdei D.

Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):43-6. Review.

PMID:
10428320
15.

[A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].

Zheng SR, Wu YY, Zhang ZL, Yang X, Hui Y, Zhang Y, Chen SL, Den WH, Liu H, Ekangaki A, Stocks J, Harper K, Liu JL.

Zhonghua Fu Chan Ke Za Zhi. 2003 Apr;38(4):226-9. Chinese.

PMID:
12885371
16.

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.

Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW.

Am J Obstet Gynecol. 1997 Dec;177(6):1458-64.

PMID:
9423751
17.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
18.

Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.

Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L Jr, Shah A, Cohen FJ.

Menopause. 1999 Fall;6(3):188-95.

PMID:
10486787
19.

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.

Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.

Bone. 2004 Feb;34(2):344-51.

PMID:
14962813
20.

Raloxifene: a selective estrogen receptor modulator.

Scott JA, Da Camara CC, Early JE.

Am Fam Physician. 1999 Sep 15;60(4):1131-9. Review.

Supplemental Content

Support Center